GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Home › GLP-1 Hub

By Dr. Frank Yap, MD  |  Last updated: October 10, 2026  |  Purpose: evidence and safety education, not individual medical advice

Quick Answer (as of October 10, 2026)

GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills: oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron), approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy.

1. Approval status at a glance

Medicine Mechanism Format US status (Oct 2026)
Semaglutide (Wegovy / Ozempic) GLP-1 Weekly injection Approved
Oral Wegovy (semaglutide 25 mg) GLP-1 Daily pill Approved Dec 2025; EU approval July 15, 2026
Tirzepatide (Mounjaro / Zepbound) GIP + GLP-1 Weekly injection Approved
Orforglipron (Foundayo) GLP-1 (non-peptide small molecule) Daily pill Approved April 1, 2026 (weight management)
CagriSema GLP-1 + amylin Injection Filed Dec 2025; decision pending
Retatrutide GIP + GLP-1 + glucagon Weekly injection Investigational; not approved

Regulatory status changes quickly. Verify against the current FDA label before acting; this table is reviewed at each update.

2. Pills vs injections

2026 is the year GLP-1 therapy moved beyond the needle. Foundayo has no food or water timing restrictions, which distinguishes it from oral semaglutide. Injectables, particularly the dual and triple agonists, currently show the largest average weight loss in trials, while pills offer convenience and different supply and cost considerations.

Best Weight Loss Peptides

  • Choose by priorities: maximum average weight loss, needle-free convenience, cost and coverage, tolerability history, and other conditions (heart, kidney, liver, sleep apnea).
  • Do not compare trials naively. Populations, durations and doses differ; head-to-head data are limited.
  • Medical supervision matters for dose escalation, side-effect management and long-term maintenance planning.

Deep-dive comparison article: coming soon in the library below.

3. Retatrutide: what is and isn't known

Retatrutide is Eli Lilly's investigational triple agonist (GIP, GLP-1 and glucagon receptors). In the Phase 3 TRIUMPH-1 trial, the 12 mg arm reported an average weight loss of about 28.3% over 80 weeks, the strongest figure reported in this drug class so far. A regulatory filing is expected around late 2026, with approval most likely in 2027 or later.

Important: Because retatrutide is not approved, any product sold as "retatrutide" outside a clinical trial is unapproved. Quality, identity and sterility cannot be assured. This hub does not provide dosing or sourcing guidance for unapproved compounds.

4. Safety, side effects and compounding risks

  • Common side effects: nausea, diarrhea, vomiting and constipation, typically worst during dose escalation.
  • Boxed warning: every approved incretin drug carries a warning about thyroid C-cell tumors. People with a personal or family history of certain thyroid cancers should discuss this with a physician.
  • Glucagon-containing agents (dual and triple agonists) require monitoring of heart rate, blood glucose and liver enzymes.
  • Compounding and telehealth: the FDA issued 30 warning letters to telehealth GLP-1 compounders on March 3, 2026. Unregulated sources have been linked to emergency-room visits.
  • Research peptides: in July 2026 an FDA advisory committee (PCAC) voted non-bindingly to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon to the compounding list. None of these is lawfully compoundable yet. See our peptide protocols guide and the peptide evidence review.

Seek urgent care for severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of an allergic reaction.

5. Evidence grades (CEBM)

We label key claims using Oxford CEBM levels (1 = systematic review or high-quality RCT; 2 = lower-quality RCT or cohort; 3 = case-control; 4 = case series; 5 = expert opinion/mechanistic). Regulatory facts are labeled "Regulatory record."

Claim Evidence Grade
Foundayo (orforglipron) FDA-approved April 1, 2026 for weight management FDA approval and label Regulatory record
Retatrutide ~28% mean weight loss (TRIUMPH-1, 80 weeks, 12 mg) Phase 3 RCT, sponsor-reported topline Level 1–2 (confirm peer-reviewed publication)
Wegovy accelerated approval for MASH with F2–F3 fibrosis ESSENCE trial and FDA decision Level 1 / Regulatory record
BPC-157, TB-500 benefits in humans Mostly animal and preclinical data Level 5 (mechanistic)
Safety of gray-market GLP-1 products FDA warning letters, reported adverse events Regulatory record / Level 4

6. Explore the full GLP-1 & peptide library

GLP-1 Knowledge graph: GLP-1 & Peptide Hub → Starting GLP-1 → muscle loss → bone density → nutrient monitoring →  side-effect management → stopping GLP-1 → personalizing treatment → Next generation (GLP 2.0)

7. Using this hub with AI assistants

AI tools can help you prepare for a physician visit, but they do not replace one. Paste the Quick Answer and status table above as context, then try these prompts. Always ask the assistant to cite sources and state its knowledge date.

Assistant Best use Sample prompt
Claude Reading long labels or trial papers and summarising caveats "Summarise this FDA label in plain English and list the warnings I should raise with my doctor."
ChatGPT Structuring a question list and visit prep "Create a checklist of questions for my first obesity-medicine appointment, including cost and coverage."
Gemini Cross-checking with recent web sources and tables "Compare currently approved GLP-1 medicines in a table, with sources and approval dates."
Perplexity Citation-first checks on breaking news "What is the latest regulatory status of retatrutide? Cite primary sources only."

8. Frequently asked questions

What is a GLP-1 medicine?

GLP-1 medicines mimic or enhance a gut hormone (glucagon-like peptide-1) that raises insulin after meals, slows stomach emptying and reduces appetite. They are prescription drugs used for type 2 diabetes and chronic weight management, and some newer agents combine GLP-1 with other hormone targets.

Which GLP-1 weight-loss pills are FDA-approved in 2026?

As of October 2026, two oral options are on the US market: oral Wegovy (semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 1, 2026), the first non-peptide oral GLP-1 for chronic weight management.

Is retatrutide FDA-approved?

No. As of October 2026, retatrutide (a GIP, GLP-1 and glucagon triple agonist) remains investigational and is not approved anywhere. Phase 3 programs are ongoing and a filing is expected around late 2026, with any approval most likely in 2027 or later.

Are compounded or gray-market GLP-1 products safe?

Compounded and online-sourced products are not FDA-approved and vary in quality, dose accuracy and sterility. The FDA issued warning letters to telehealth GLP-1 compounders in March 2026. Use a licensed physician and a regulated pharmacy.

What are the most common GLP-1 side effects?

Nausea, diarrhea, vomiting and constipation are most common, typically worst during dose escalation. Approved incretin drugs carry a boxed warning for thyroid C-cell tumors. Discuss your history with a physician before starting.

Are GLP-1 pills as effective as injections?

Head-to-head evidence is limited and results differ by drug and trial population. Injectable agents currently show the largest average weight loss, while pills offer convenience and different access options. Your physician can match the format to your goals, history and cost.

9. Disclosures & sources

Affiliate disclosure: Some links on One Day MD, including to The Wellness Company (referral code ONEDAYMD) and Amazon (as an Amazon Associate we earn from qualifying purchases), may earn us a commission at no extra cost to you. Affiliate relationships do not influence our evidence grading or safety statements, and no affiliate product is a substitute for prescribed GLP-1 therapy.

Medical disclaimer: This page is educational and does not constitute medical advice, diagnosis or treatment. Consult a licensed physician before starting, changing or stopping any medication.

Primary sources to verify: FDA Drugs@FDA labels (Wegovy, Zepbound, Foundayo); FDA compounding and warning-letter notices; ClinicalTrials.gov (TRIUMPH program); European Commission and EMA announcements; Malaysia NPRA and Singapore HSA registers.

Update log: Oct 10, 2026, initial publication of GLP-1 Hub.

Comments

Post a Comment

Popular posts from this blog

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2, 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that ad...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive re...
Read more

Ozempic vs Wegovy vs Mounjaro vs Trulicity: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

Image
GLP-1 & Obesity Medicine Guide • Updated October 2026 Ozempic, Wegovy, Mounjaro and Trulicity are all once-weekly injectable medicines, but they are not the same drug and they are not approved for exactly the same purposes. Ozempic and Wegovy contain semaglutide ; Trulicity contains dulaglutide ; and Mounjaro contains tirzepatide , a dual GIP/GLP-1 receptor agonist. For weight loss , the strongest head-to-head evidence currently favors tirzepatide over semaglutide. In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide versus 13.7% with semaglutide . For type 2 diabetes , tirzepatide has also produced greater weight loss and HbA1c reduction than semaglutide 1 mg in SURPASS-2, although that trial does not prove that tirzepatide is superior to every semaglutide dose or every patient-specific regimen. At the same time, “best” depends on the goal . Semaglutide has extensive cardiovascular and kid...
Read more

Ozempic vs Wegovy vs Mounjaro vs Zepbound: Differences, Evidence, Safety and Access (2026)

Image
By Dr. Frank Yap, MD, One Day Media Network · Published 2026-10-04 · Last updated 2026-10-04 · Reading time about 12 minutes Quick Answer Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. The right choice depends on diagnosis, coverage, tolerability and other conditions. In this article Are these four drugs different or the same? Side-by-side comparison table Which produces more weight loss? Heart, kidney, liver and sleep apnea indications Side effects and who should avoid the...
Read more

Telehealth Peptide Providers 2026: How to Compare Prescription GLP-1s, Other Peptides, Compounding, Clinical Oversight and Pharmacy Sources

Image
A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...
Read more

Semaglutide vs Tirzepatide vs Orforglipron: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

Image
GLP-1 & Obesity Medicine Guide • Updated October 2026 Semaglutide, tirzepatide and orforglipron represent three important stages in the evolution of incretin-based medicine: an established injectable GLP-1 receptor agonist, a dual GIP/GLP-1 agonist with greater average weight loss, and a next-generation oral GLP-1 receptor agonist designed to deliver GLP-1 therapy without an injection. But the phrase “best GLP-1 drug” can be misleading. These medicines do not have identical mechanisms, routes of administration, dose scales, indications or clinical-outcome evidence. And the headline weight-loss percentages come from different trials, so they cannot simply be placed in one league table as though the three drugs were tested against each other in a single randomized trial. The current evidence nevertheless gives us a useful framework. Tirzepatide currently has the strongest direct evidence for greater weight loss than semaglutide. Semaglutide remains a benchmark therapy w...
Read more

Tirzepatide vs Semaglutide: Zepbound vs Wegovy for Weight Loss, Diabetes & Heart Health in 2026

Image
2026 Evidence-Based Guide Last updated: October 6, 2026. Tirzepatide and semaglutide are two of the most important incretin-based medicines used for obesity and metabolic disease. The key question is no longer simply whether they work. It is which drug has the better evidence for a particular goal, patient and indication . Bottom line: In the strongest direct head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide : 20.2% versus 13.7% at 72 weeks in SURMOUNT-5. However, semaglutide has important advantages, including a mature cardiovascular-outcomes evidence base, an oral Wegovy formulation, an FDA-approved 7.2-mg injectable dose for selected adults, pediatric obesity approval for Wegovy injection, and an FDA-approved MASH indication for Wegovy injection. This guide focuses on U.S. regulatory labeling and major published evidence. Drug approvals, formulations, availability and prescribing rules differ by co...
Read more

Fatty Liver (MASLD/MASH): Diagnosis, FIB-4 Score, Treatment Ladder & Supplement Evidence 2026

Image
OneDayMD Research Team • Updated October 2026 A practical guide to metabolic dysfunction-associated steatotic liver disease: how to recognize fatty liver, estimate fibrosis risk with FIB-4, decide when FibroScan or specialist assessment is needed, and understand what actually works in 2026. The key idea: fatty liver is not simply a problem of “too much fat in the liver.” The clinically important question is whether there is inflammation and, especially, significant liver fibrosis . That changes the level of risk and the treatment conversation. OneDayMD bottom line: For most adults with suspected MASLD, the practical pathway is identify metabolic risk → calculate FIB-4 → use a second non-invasive test when indicated → stage fibrosis → treat weight, glucose, lipids and cardiovascular risk → consider MASH-targeted medication when significant fibrosis is present . Supplements remain secondary because guideline-level evidence is not strong enough to recom...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
2026 Evidence & Treatment Guide GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly . The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals. Updated: September 27, 2026   |   Regulatory reference: U.S. FDA labeling   |   Scope: Adult obesity treatment unless otherwise stated Important medical note: This page is educational information, not a diagnosis or personal treatm...
Read more